ClinicalTrials.gg
CompletedNCT03464045Updated Apr 20, 2025Results posted

Empa PASS on Urinary Tract Malignancies

An observational study in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-20.

Sponsored by Boehringer Ingelheim · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
344,995
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim — 2 open to participants now, 3 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Boehringer Ingelheim.

Enrollment
5th of 34
344,995 · median 10,286
Started
2016
with 5 others
Observational
34 of 130
none open now
Registered
108th of 130
by date

Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 5th largest by enrollment of the 34 observational ones that give a count, is one of 6 that started in 2016, is one of 34 observational ones, and was the 108th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, or all of them as a file.
02

Study summary

The aim of the study is to assess the risk of urinary tract malignancies in patients initiating empagliflozin (free or fixed dose combination) compared to patients initiating a dipeptidyl peptidase-4 (DPP-4) inhibitor.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

This is an observational, comparative, cohort safety study based on European healthcare databases and includes databases from the UK, Finland, and Sweden.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of type 2 diabetes
  • Age over 18 years at index date
  • At least 1 year of membership in the medication database prior to index date

Exclusion criteria

Exclusion Criteria:

  • Patients with any cancer (excluding non-melanoma skin cancer) recorded at any time prior to the index date (i.e. during the available look-back time)
  • Diagnosis of type 1 diabetes or other specific non-type 2 diabetes
  • Use of any SGLT-2 inhibitor or any DPP-4 inhibitor (including free and fixed-dose combinations) recorded at any time prior to index date (i.e. during the available look-back time).
  • Use of fixed-dose combinations of SGLT-2 inhibitors with DPP-4 inhibitors
  • Diagnosis of end stage renal disease or receipt of renal dialysis recorded at any time prior to index date (i.e. during the available look-back time)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
344,995 participants (actual)
Patient registry
No

Groups and cohorts

  • Empagliflozin initiators - UK

    Participants with Type 2 diabetes mellitus (T2D) initiating (first purchase/prescription) empagliflozin (study drug), in free form or in fixed-dose combination with metformin, between 1-Aug-2014 and 31-Dec-2021 (index date), and with more than 6 months of possible follow-up (index date less than 6 months prior to end of study date). The study population was identified from Clinical Practice Research Datalink (CPRD) (General practitioner Online Data \[GOLD\], and Aurum) in the United Kingdom (UK).

    Drug: empagliflozin

  • DPP4-i initiators - UK

    Participants with T2D initiating (first purchase/prescription) a dipeptidyl peptidase-4 inhibitor (DPP-4i) (comparator), in free form or in fixed-dose combination with metformin, between 1-Aug-2014 and 31-Dec-2021 (index date), and with more than 6 months of possible follow-up (index date less than 6 months prior to end of study date). The study population was identified from CPRD (General practitioner Online Data \[GOLD\], and Aurum) in the UK.

    Drug: DPP-4 inhibitors

  • Empagliflozin initiators - Sweden

    Participants with T2D initiating (first purchase/prescription) empagliflozin (study drug), in free form or in fixed-dose combination with metformin, between 1-Aug-2014 and 31-Dec-2020 (index date), and with more than 6 months of possible follow-up (index date less than 6 months prior to end of study date). The study population was identified from the nationwide registers in Sweden.

    Drug: empagliflozin

  • DPP4-i initiators - Sweden

    Participants with T2D initiating (first purchase/prescription) a dipeptidyl peptidase-4 inhibitor (DPP-4i) (comparator), in free form or in fixed-dose combination with metformin, between 1-Aug-2014 and 31-Dec-2020 (index date), and with more than 6 months of possible follow-up (index date less than 6 months prior to end of study date). The study population was identified from the nationwide registers in Sweden.

    Drug: DPP-4 inhibitors

  • Empagliflozin initiators - Finland

    Participants with T2D initiating (first purchase/prescription) empagliflozin (study drug), in free form or in fixed-dose combination with metformin, between 1-Aug-2014 and 31-Dec-2020 (index date), and with more than 6 months of possible follow-up (index date less than 6 months prior to end of study date). The study population was identified from the nationwide registers in Finland.

    Drug: empagliflozin

  • DPP4-i initiators - Finland

    Participants with T2D initiating (first purchase/prescription) a dipeptidyl peptidase-4 inhibitor (DPP-4i) (comparator), in free form or in fixed-dose combination with metformin, between 1-Aug-2014 and 31-Dec-2020 (index date), and with more than 6 months of possible follow-up (index date less than 6 months prior to end of study date). The study population was identified from the nationwide registers in Finland.

    Drug: DPP-4 inhibitors

Interventions

06

What researchers measure

Primary outcomes

  1. Occurrence of Urinary Tract Cancer

    Occurrence of urinary tract cancer, which include malignant neoplasm and carcinoma in situ of the urinary tract, is reported as incidence rates per 1000 patient years. Incidence rates were estimated using Poisson regression and computed as the number of outcome events divided by the total person-time-at-risk (in years), multiplied by 1,000 for easier comparison. The country-level datasets were analyzed separately. Thereafter, pooled incidence rates were estimated using the aggregated number of outcome events and time-at-risk of all study countries using the Poisson regression.

    Time frame: From 181 days after index date until the occurrence of a censoring event or cancer outcome event. Up to 6 (Sweden/Finland) or 7 years (UK).

  2. Occurrence of Bladder Cancer

    Occurrence of bladder cancer, malignant and carcinoma in situ, is reported as incidence rates per 1000 patient years. Incidence rates were estimated using Poisson regression and computed as the number of outcome events divided by the total person-time-at-risk (in years), multiplied by 1,000 for easier comparison. The country-level datasets were analyzed separately. Thereafter, pooled incidence rates were estimated using the aggregated number of outcome events and time-at-risk of all study countries using the Poisson regression.

    Time frame: From 181 days after index date until the occurrence of a censoring event or cancer outcome event. Up to 6 (Sweden/Finland) or 7 years (UK).

  3. Occurrence of Renal Cancer

    Occurrence of malignant renal cancer is reported as incidence rates per 1000 patient years. Incidence rates were estimated using Poisson regression and computed as the number of outcome events divided by the total person-time-at-risk (in years), multiplied by 1,000 for easier comparison. The country-level datasets were analyzed separately. Thereafter, pooled incidence rates were estimated using the aggregated number of outcome events and time-at-risk of all study countries using the Poisson regression.

    Time frame: From 181 days after index date until the occurrence of a censoring event or cancer outcome event. Up to 6 (Sweden/Finland) or 7 years (UK).

07

Results

Posted Mar 28, 2025

Participant flow

This was a non-interventional, comparative, cohort-based Post-authorisation-safety study (PASS) to assess the risk of urinary tract malignancies in patients affected by type 2 diabetes mellitus initiating empagliflozin or dipeptidyl peptidase-4 inhibitor (DPP-4i) between 1-Aug-2014 and 31-Dec-2021 in the United Kingdom (UK), Sweden, and Finland.

Participant flow — Overall Study
MilestoneEmpagliflozin Initiators - UKDPP4-i Initiators - UKEmpagliflozin Initiators - SwedenDPP4-i Initiators - SwedenEmpagliflozin Initiators - FinlandDPP4-i Initiators - Finland
Started2741012333435954736232194262732
Completed2741012333435954736232194262732
Not completed000000

Outcome measures

PrimaryOccurrence of Urinary Tract Cancer

Occurrence of urinary tract cancer, which include malignant neoplasm and carcinoma in situ of the urinary tract, is reported as incidence rates per 1000 patient years. Incidence rates were estimated using Poisson regression and computed as the number of outcome events divided by the total person-time-at-risk (in years), multiplied by 1,000 for easier comparison. The country-level datasets were analyzed separately. Thereafter, pooled incidence rates were estimated using the aggregated number of outcome events and time-at-risk of all study countries using the Poisson regression.

Time frame:
From 181 days after index date until the occurrence of a censoring event or cancer outcome event. Up to 6 (Sweden/Finland) or 7 years (UK).
Reported as:
Number · Events per 1000 patient years
Occurrence of Urinary Tract Cancer
Events per 1000 patient yearsEmpagliflozin Initiators - UK, PS-matchedDPP4-i Initiators - UK, PS-matchedEmpagliflozin Initiators - Sweden, PS-matchedDPP4-i Initiators - Sweden, PS-matchedEmpagliflozin Initiators - Finland, PS-matchedDPP4-i Initiators - Finland, PS-matchedEmpagliflozin Initiators - All Countries, PS-matchedDPP4-i Initiators - All Countries, PS-matched
Occurrence of Urinary Tract Cancer0.73 (0.46 to 1.16)1.07 (0.84 to 1.37)1.34 (0.95 to 1.89)1.52 (1.13 to 2.05)1.27 (0.86 to 1.87)1.49 (1.13 to 1.96)1.10 (0.88 to 1.38)1.29 (1.11 to 1.51)
Statistical analysis
  • Empagliflozin Initiators - UK, PS-matched vs DPP4-i Initiators - UK, PS-matched vs Empagliflozin Initiators - Sweden, PS-matched vs DPP4-i Initiators - Sweden, PS-matched vs Empagliflozin Initiators - Finland, PS-matched vs DPP4-i Initiators - Finland, PS-matched · Regression, Cox · p = 0.122 · Hazard ratio (hr): 0.80 · 95% CI 0.61 to 1.06Crude hazard ratio of empagliflozin/DPP-4i
  • Empagliflozin Initiators - UK, PS-matched vs DPP4-i Initiators - UK, PS-matched vs Empagliflozin Initiators - Sweden, PS-matched vs DPP4-i Initiators - Sweden, PS-matched vs Empagliflozin Initiators - Finland, PS-matched vs DPP4-i Initiators - Finland, PS-matched · Regression, Cox · p = 0.417 · Hazard ratio (hr): 0.89 · 95% CI 0.67 to 1.18Base hazard ratio of empagliflozin/DPP-4i
  • Empagliflozin Initiators - UK, PS-matched vs DPP4-i Initiators - UK, PS-matched vs Empagliflozin Initiators - Sweden, PS-matched vs DPP4-i Initiators - Sweden, PS-matched vs Empagliflozin Initiators - Finland, PS-matched vs DPP4-i Initiators - Finland, PS-matched · Regression, Cox · p = 0.376 · Hazard ratio (hr): 0.88 · 95% CI 0.66 to 1.17Adjusted hazard ratio of empagliflozin/DPP-4i
PrimaryOccurrence of Bladder Cancer

Occurrence of bladder cancer, malignant and carcinoma in situ, is reported as incidence rates per 1000 patient years. Incidence rates were estimated using Poisson regression and computed as the number of outcome events divided by the total person-time-at-risk (in years), multiplied by 1,000 for easier comparison. The country-level datasets were analyzed separately. Thereafter, pooled incidence rates were estimated using the aggregated number of outcome events and time-at-risk of all study countries using the Poisson regression.

Time frame:
From 181 days after index date until the occurrence of a censoring event or cancer outcome event. Up to 6 (Sweden/Finland) or 7 years (UK).
Reported as:
Number · Events per 1000 patient years
Occurrence of Bladder Cancer
Events per 1000 patient yearsEmpagliflozin Initiators - UK, PS-matchedDPP4-i Initiators - UK, PS-matchedEmpagliflozin Initiators - Sweden, PS-matchedDPP4-i Initiators - Sweden, PS-matchedEmpagliflozin Initiators - Finland, PS-matchedDPP4-i Initiators - Finland, PS-matchedEmpagliflozin Initiators - All Countries, PS-matchedDPP4-i Initiators - All Countries, PS-matched
Occurrence of Bladder Cancer0.45 (0.25 to 0.81)0.67 (0.49 to 0.90)0.92 (0.61 to 1.40)1.03 (0.71 to 1.48)0.51 (0.27 to 0.94)0.64 (0.42 to 0.98)0.63 (0.47 to 0.85)0.74 (0.6 to 0.91)
Statistical analysis
  • Empagliflozin Initiators - UK, PS-matched vs DPP4-i Initiators - UK, PS-matched vs Empagliflozin Initiators - Sweden, PS-matched vs DPP4-i Initiators - Sweden, PS-matched vs Empagliflozin Initiators - Finland, PS-matched vs DPP4-i Initiators - Finland, PS-matched · Regression, Cox · p = 0.220 · Hazard ratio (hr): 0.79 · 95% CI 0.55 to 1.15Crude hazard ratio of empagliflozin/DPP-4i
  • Empagliflozin Initiators - UK, PS-matched vs DPP4-i Initiators - UK, PS-matched vs Empagliflozin Initiators - Sweden, PS-matched vs DPP4-i Initiators - Sweden, PS-matched vs Empagliflozin Initiators - Finland, PS-matched vs DPP4-i Initiators - Finland, PS-matched · Regression, Cox · p = 0.628 · Hazard ratio (hr): 0.91 · 95% CI 0.63 to 1.32Base hazard ratio of empagliflozin/DPP-4i
  • Empagliflozin Initiators - UK, PS-matched vs DPP4-i Initiators - UK, PS-matched vs Empagliflozin Initiators - Sweden, PS-matched vs DPP4-i Initiators - Sweden, PS-matched vs Empagliflozin Initiators - Finland, PS-matched vs DPP4-i Initiators - Finland, PS-matched · Regression, Cox · p = 0.632 · Hazard ratio (hr): 0.91 · 95% CI 0.63 to 1.33Adjusted hazard ratio of empagliflozin/DPP-4i
PrimaryOccurrence of Renal Cancer

Occurrence of malignant renal cancer is reported as incidence rates per 1000 patient years. Incidence rates were estimated using Poisson regression and computed as the number of outcome events divided by the total person-time-at-risk (in years), multiplied by 1,000 for easier comparison. The country-level datasets were analyzed separately. Thereafter, pooled incidence rates were estimated using the aggregated number of outcome events and time-at-risk of all study countries using the Poisson regression.

Time frame:
From 181 days after index date until the occurrence of a censoring event or cancer outcome event. Up to 6 (Sweden/Finland) or 7 years (UK).
Reported as:
Number · Events per 1000 patient years
Occurrence of Renal Cancer
Events per 1000 patient yearsEmpagliflozin Initiators - UK, PS-matchedDPP4-i Initiators - UK, PS-matchedEmpagliflozin Initiators - Sweden, PS-matchedDPP4-i Initiators - Sweden, PS-matchedEmpagliflozin Initiators - Finland, PS-matchedDPP4-i Initiators - Finland, PS-matchedEmpagliflozin Initiators - All Countries, PS-matchedDPP4-i Initiators - All Countries, PS-matched
Occurrence of Renal Cancer0.24 (0.11 to 0.54)0.34 (0.22 to 0.52)0.42 (0.22 to 0.78)0.50 (0.29 to 0.84)0.76 (0.46 to 1.26)0.82 (0.57 to 1.19)0.45 (0.32 to 0.65)0.51 (0.4 to 0.65)
Statistical analysis
  • Empagliflozin Initiators - UK, PS-matched vs DPP4-i Initiators - UK, PS-matched vs Empagliflozin Initiators - Sweden, PS-matched vs DPP4-i Initiators - Sweden, PS-matched vs Empagliflozin Initiators - Finland, PS-matched vs DPP4-i Initiators - Finland, PS-matched · Regression, Cox · p = 0.420 · Hazard ratio (hr): 0.84 · 95% CI 0.54 to 1.29Crude hazard ratio of empagliflozin/DPP-4i
  • Empagliflozin Initiators - UK, PS-matched vs DPP4-i Initiators - UK, PS-matched vs Empagliflozin Initiators - Sweden, PS-matched vs DPP4-i Initiators - Sweden, PS-matched vs Empagliflozin Initiators - Finland, PS-matched vs DPP4-i Initiators - Finland, PS-matched · Regression, Cox · p = 0.606 · Hazard ratio (hr): 0.89 · 95% CI 0.57 to 1.38Base hazard ratio of empagliflozin/DPP-4i
  • Empagliflozin Initiators - UK, PS-matched vs DPP4-i Initiators - UK, PS-matched vs Empagliflozin Initiators - Sweden, PS-matched vs DPP4-i Initiators - Sweden, PS-matched vs Empagliflozin Initiators - Finland, PS-matched vs DPP4-i Initiators - Finland, PS-matched · Regression, Cox · p = 0.609 · Hazard ratio (hr): 0.89 · 95% CI 0.57 to 1.38Adjusted hazard ratio of empagliflozin/DPP-4i

Adverse events

Collected over This study used secondary data only. Hence, reporting of adverse reactions was not required nor possible.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Empagliflozin Initiators - UK———
DPP4-i Initiators - UK———
Empagliflozin Initiators - Sweden———
DPP4-i Initiators - Sweden———
Empagliflozin Initiators - Finland———
DPP4-i Initiators - Finland———

Baseline characteristics

Study population: population before propensity score-matching.

Age, Continuous
Age, Continuous(Years)Empagliflozin Initiators - UKDPP4-i Initiators - UKEmpagliflozin Initiators - SwedenDPP4-i Initiators - SwedenEmpagliflozin Initiators - FinlandDPP4-i Initiators - FinlandTotal
Mean56.51 ± 10.9663.50 ± 13.2462.75 ± 11.1866.65 ± 12.6660.11 ± 11.8466.04 ± 13.4263.78 ± 12.93
Sex: Female, Male
Sex: Female, Male(Participants)Empagliflozin Initiators - UKDPP4-i Initiators - UKEmpagliflozin Initiators - SwedenDPP4-i Initiators - SwedenEmpagliflozin Initiators - FinlandDPP4-i Initiators - FinlandTotal
Female169227212424825443521304834233205504
Male10488512101112929271889428499139491
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Empagliflozin Initiators - UKDPP4-i Initiators - UKEmpagliflozin Initiators - SwedenDPP4-i Initiators - SwedenEmpagliflozin Initiators - FinlandDPP4-i Initiators - FinlandTotal
Count of participants——————0
08

Study locations

3 sites
  • The National Register Data
    Helsinki, Finland
  • The Swedish prescribed drug register
    Stockholm, Sweden
  • United Kingdom Clinical Practice Research Datalink (CPRD)
    London, United Kingdom
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Mar 2024, 87 months.

Results were first posted in Mar 2025, 1 year after primary completion.

Of 170 industry-sponsored observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 44. This study's 87 months is above that.

Counting every sponsor, half of 603 studies reached it within 32 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2018
First posted
Mar 13, 2018
StartActual
Nov 16, 2016
Primary completionActual
Mar 11, 2024
CompletionActual
Mar 11, 2024
Results first posted
Mar 28, 2025
Last update
Apr 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03464045
Responsible party
Sponsor
First posted
Mar 13, 2018
Start date
Nov 16, 2016
Primary completion
Mar 11, 2024
Completion
Mar 11, 2024
Results posted
Mar 28, 2025
Last update
Apr 20, 2025

Study contacts

Pasi Korhonen, 358-50-3652990
principal investigator · pasi.korhonen@epidresearch.com
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion